Last $0.01 USD
Change Today 0.00 / 0.00%
Volume 0.0
NEUKF On Other Exchanges
Symbol
Exchange
OTC BB
Berlin
As of 8:10 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

neurokine pharmaceuticals (NEUKF) Snapshot

Open
$0.01
Previous Close
$0.01
Day High
$0.01
Day Low
$0.01
52 Week High
03/28/14 - $0.04
52 Week Low
04/30/14 - $0.0018
Market Cap
1.4M
Average Volume 10 Days
2.8K
EPS TTM
$0.0020
Shares Outstanding
115.8M
EX-Date
--
P/E TM
6.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for NEUROKINE PHARMACEUTICALS (NEUKF)

Related News

No related news articles were found.

neurokine pharmaceuticals (NEUKF) Related Businessweek News

No Related Businessweek News Found

neurokine pharmaceuticals (NEUKF) Details

Neurokine Pharmaceuticals Inc., a development stage company, is engaged in the development and commercialization of therapeutic pharmaceutical products. The company focuses on biologics comprising vaccines, blood, and blood components; allergenics; somatic cells relating to the wall of the body cavity; gene therapy; tissues; and recombinant therapeutics that cause cell death in tumors. Its products under the developmental stage include NK-001 for the potential treatment of neurocognitive impairment in post-coronary artery bypass graft surgery patients; and NK-002 for the potential treatment of Alzheimer’s disease. The company was formerly known as Xerxes Health Corp. and changed its name to Neurokine Pharmaceuticals Inc. in June 2007. Neurokine Pharmaceuticals Inc. was founded in 2002 and is based in Vancouver, Canada.

neurokine pharmaceuticals (NEUKF) Top Compensated Officers

Chief Executive Officer, President and Secret...
Total Annual Compensation: --
Chief Financial Officer and Principal Account...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

neurokine pharmaceuticals (NEUKF) Key Developments

Neurokine Pharmaceuticals Inc. announced delayed annual 10-K filing

On 05/02/2014, Neurokine Pharmaceuticals Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Neurokine Pharmaceuticals Inc. proposes Amendments to the Articles of Incorporation

Neurokine Pharmaceuticals Inc. announced that the annual and special meeting of stockholders of the company to be held on June 3, 2014, to approve an amendment to the company’s Articles of Incorporation to increase the authorized number common shares from 200,000,000 common shares, without par value to an unlimited number of common shares, without par value.

Neurokine Pharmaceuticals Inc., Annual General Meeting, Jun 03, 2014

Neurokine Pharmaceuticals Inc., Annual General Meeting, Jun 03, 2014., at 10:00 Pacific Standard Time. Location: 400 - 570 Granville Street. Agenda: To elect Ahmad Doroudian, Maziar Badii, and Richard Azani to serve as Directors of the company; to ratify the appointment of Sadler Gibb & Associates, LLC as its independent public accounting firm for the year ending January 31, 2015; to conduct an advisory vote on the compensation of the company's named Executive Officers; to conduct an advisory vote on the frequency of future advisory votes on the compensation of the company's named Executive Officers; to approve an amendment to the company’s Articles of Incorporation to increase the authorized number common shares from 200,000,000 common shares, without par value to an unlimited number of common shares, without par value; and to transact such other business as may properly come before the Meeting or any adjournment or postponement thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEUKF:US $0.01 USD 0.00

NEUKF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NEUKF.
View Industry Companies
 

Industry Analysis

NEUKF

Industry Average

Valuation NEUKF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROKINE PHARMACEUTICALS, please visit www.neurokine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.